Cannovum AG

  • WKN: A2LQU2
  • ISIN: DE000A2LQU21
  • Land: Deutschland

Nachricht vom 24.06.2021 | 09:06

Cannovum AG enters supply agreement for medical cannabis with Aurora Europe

DGAP-News: Cannovum AG / Key word(s): Product Launch
24.06.2021 / 09:06
The issuer is solely responsible for the content of this announcement.

Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has entered into a long term supply agreement with Aurora through its licensed subsidiary, Cannovum Health eG. Starting today, Cannovum will distribute the full range of medical cannabis products offered by Aurora to pharmacies throughout Germany.

The canadian company Aurora is one of the largest authorised manufacturers of medical cannabis in the European Union. After the German legalization of medical cannabis in 2017 Aurora joined the German market with their acquisition of the German company Pedanios, thus making Aurora / Pedanios products one of the first cannabis medicines available in Germany. This allowed doctors and pharmacists to gain experience in treating their patients with these products.
Expanding the medical cannabis portfolio with the full range of Aurora products is therefore an important step for Cannovum towards ensuring best possible patient care.

"We want to support doctors and pharmacists in finding the appropriate treatment for their patients. In order for us to achieve that, we need to provide a full portfolio of medical cannabis which gives them the opportunity to fully customize the therapy. By partnering with Aurora we are confident that we continue to provide high quality medication to ensure every patient receives the best therapy", says Pia Marten, CEO of Cannovum AG.

Cannovum's own team of pharmaceutical representatives has received intensive training in the new products, in order to confidently advise pharmacists and doctors.


Contact:

Linda Rasch, IR & PR, Cannovum AG
Phone +49 30 3982 163 62, linda.rasch@cannovum.com

Cannovum AG is the first German listed medical cannabis company. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.

For more information, visit www.cannovum.com



24.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Cryptology Asset Group PLC: 120 % Kurspotenzial

GBC Research hat mit der Coverage der Cryptology Asset Group PLC (ISIN: MT0001770107) begonnen. Die Bewertung der führenden europäischen Investmentgesellschaft für Krypto-Assets und Blockchain-Unternehmen erfolgte mittels der Berechnung des Net Asset Value (NAV). Unter Berücksichtigung aller Beteiligungen ergibt sich zum 05. Juli 2021 eine GBC-Fair-NAV-Bewertung in Höhe von 1,04 Mrd. EUR. Daraus ergibt sich ein NAV je Cryptology-Aktie von 358,43 EUR. Daher empfiehlt GBC Research die Cryptology-Aktie zum Kauf und sieht ein Kurspotenzial von über 120 %.

News im Fokus

RWE Aktiengesellschaft: RWE AG erhöht Konzern-Ergebnisprognose für das Geschäftsjahr 2021

30. Juli 2021, 08:52

Aktueller Webcast

HENSOLDT AG

H1 2021 Analyst Call

04. August 2021

Aktuelle Research-Studie

q.beyond AG

Original-Research: q.beyond AG (von Montega AG): Kaufen

29. Juli 2021